How does cosentyx impact pregnancy outcomes?

How do animal studies describe cosentyx safety in pregnancy?

Animal reproduction studies with secukinumab showed no evidence of embryofetal toxicity or teratogenicity at doses up to 150 times the maximum recommended human dose. No maternal toxicity was observed either. These results came from studies in monkeys and mice.

How does human data compare to animal results?

Limited human data exist. From a small number of pregnancy cases collected through registries and spontaneous reports, outcomes appeared consistent with background population rates. No specific pattern of major birth defects emerged. Still, the manufacturer recommends avoiding Cosentyx during pregnancy unless the potential benefit justifies the risk.

Can women take Cosentyx while planning pregnancy?

Current guidelines advise stopping Cosentyx at least 19 weeks before conception because of the drug's half-life. Some clinicians may decide to continue treatment if disease activity poses a greater risk. Individual risk-benefit assessments guide these decisions.

What happens if a woman becomes pregnant on Cosentyx?

Women who conceive while taking Cosentyx should enroll in the Novartis pregnancy registry. The company tracks outcomes to build better data. Doctors usually weigh whether to stop or keep the drug based on how well the patient has managed her condition with Cosentyx.

Why are companies challenging this patent?

Novartis holds several patents covering secukinumab formulations and manufacturing methods. Generic and biosimilar makers have filed challenges in multiple jurisdictions. The earliest patent expiry for basic composition-of-matter protection is 2025 in the US.